HHS Public Access Author manuscript Author Manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01. Published in final edited form as:
Cancer Epidemiol Biomarkers Prev. 2016 April ; 25(4): 593–602. doi:10.1158/1055-9965.EPI-15-1243.
Results of a Multi-level Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls Electra D. Paskett1,2,3, Jessica L. Krok-Schoen1, Michael L. Pennell4, Cathy M. Tatum1, Paul L. Reiter1,2,3, Juan Peng4, Brittany M. Bernardo1, Rory C. Weier5, Morgan S. Richardson6, and Mira L. Katz1,2,7 1Comprehensive
Author Manuscript
Cancer Center, The Ohio State University, 1590 N. High St., Suite 525, Columbus, OH 43201
2Division
of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, 395 W. 12th Ave., Columbus, OH 43210
3Division
of Epidemiology, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
4Division
of Biostatistics, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
5Partners
for Kids, 525 East Mound St., 3rd Floor, Columbus, OH 43205
6Department
Author Manuscript
of Neurology, College of Medicine, The Ohio State University, 2006-2030 Kenny Rd., Columbus, OH 43221 7Division
of Health Behavior and Health Promotion, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
Abstract Background—Uptake of the human papillomavirus (HPV) vaccine is low in Appalachian Ohio, and area with high cervical cancer rates.
Author Manuscript
Methods—We conducted a group-randomized trial among 12 counties in Appalachian Ohio randomized to receive either an HPV vaccine (intervention counties) or influenza vaccine (comparison counties) multi-level intervention (MLI). Parents (n=337) who had a daughter aged 9 to 17 years who had not received the HPV vaccine were recruited from commercial lists. Clinics (N=24) and 119 providers from these clinics were also recruited. The primary outcome was medical record confirmed receipt of the first shot of the HPV vaccine three months after receiving the intervention among daughters of parents enrolled in the study. Secondary outcomes included receipt of the first HPV vaccine shot by 6 months and changes in provider knowledge. Results—According to medical records, 10 (7.7%) daughters of intervention participants received the first shot of the HPV vaccine within three months of being sent the intervention materials compared to 4 (3.2%) daughters of comparison group participants (p=0.061). By six
Conflict of Interest Statement: E.D. Paskett has received research grants from Merck Sharp & Dohme Corp. P.L. Reiter has received research grants from Merck Sharp & Dohme Corp. and Cervical Cancer-Free America, via an unrestricted educational grant from GlaxoSmithKline. These funds were not used to support this research study.
Paskett et al.
Page 2
Author Manuscript
months, 17 (13.1%) daughters of intervention participants received the first HPV vaccine shot compared to eight (6.5%) daughters of comparison group participants (p=0.002). Provider knowledge about HPV increased (p
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01. Published in final edited form as:
Cancer Epidemiol Biomarkers Prev. 2016 April ; 25(4): 593–602. doi:10.1158/1055-9965.EPI-15-1243.
Results of a Multi-level Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls Electra D. Paskett1,2,3, Jessica L. Krok-Schoen1, Michael L. Pennell4, Cathy M. Tatum1, Paul L. Reiter1,2,3, Juan Peng4, Brittany M. Bernardo1, Rory C. Weier5, Morgan S. Richardson6, and Mira L. Katz1,2,7 1Comprehensive
Author Manuscript
Cancer Center, The Ohio State University, 1590 N. High St., Suite 525, Columbus, OH 43201
2Division
of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, 395 W. 12th Ave., Columbus, OH 43210
3Division
of Epidemiology, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
4Division
of Biostatistics, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
5Partners
for Kids, 525 East Mound St., 3rd Floor, Columbus, OH 43205
6Department
Author Manuscript
of Neurology, College of Medicine, The Ohio State University, 2006-2030 Kenny Rd., Columbus, OH 43221 7Division
of Health Behavior and Health Promotion, College of Public Health, The Ohio State University, 1841 Neil Ave., Columbus, OH 43210
Abstract Background—Uptake of the human papillomavirus (HPV) vaccine is low in Appalachian Ohio, and area with high cervical cancer rates.
Author Manuscript
Methods—We conducted a group-randomized trial among 12 counties in Appalachian Ohio randomized to receive either an HPV vaccine (intervention counties) or influenza vaccine (comparison counties) multi-level intervention (MLI). Parents (n=337) who had a daughter aged 9 to 17 years who had not received the HPV vaccine were recruited from commercial lists. Clinics (N=24) and 119 providers from these clinics were also recruited. The primary outcome was medical record confirmed receipt of the first shot of the HPV vaccine three months after receiving the intervention among daughters of parents enrolled in the study. Secondary outcomes included receipt of the first HPV vaccine shot by 6 months and changes in provider knowledge. Results—According to medical records, 10 (7.7%) daughters of intervention participants received the first shot of the HPV vaccine within three months of being sent the intervention materials compared to 4 (3.2%) daughters of comparison group participants (p=0.061). By six
Conflict of Interest Statement: E.D. Paskett has received research grants from Merck Sharp & Dohme Corp. P.L. Reiter has received research grants from Merck Sharp & Dohme Corp. and Cervical Cancer-Free America, via an unrestricted educational grant from GlaxoSmithKline. These funds were not used to support this research study.
Paskett et al.
Page 2
Author Manuscript
months, 17 (13.1%) daughters of intervention participants received the first HPV vaccine shot compared to eight (6.5%) daughters of comparison group participants (p=0.002). Provider knowledge about HPV increased (p
